This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harper DM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247–1255
Cuzick J et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095–1101
Ronco G et al. (2006) Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98: 765–774
Bulkmans NW et al: High-risk human papillomavirus testing detects cervical intraepithelial neoplasia grade 3 and cancer earlier than cytology in cervical screening permitting extension of the screening interval: five-year follow-up results of the randomised controlled POBASCAM trial. Lancet, in press.
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CJLM Meijer is a consultant for Digene and has obtained lecture fees from Digene and GlaxoSmithKline. He has received unrestricted grants from GlaxoSmithKline.
The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Meijer, C., Berkhof, J., Heideman, D. et al. Cervical cancer prevention: who should receive vaccination?. Nat Rev Clin Oncol 5, 12–13 (2008). https://doi.org/10.1038/ncponc0976
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0976